Moreover, as RBM3 has been demonstrated to be a good prognostic biomarker in several other cancer forms, e.g. breast cancer [14] and ovarian cancer [15], its clinical utility in stratification of melanoma patients should be validated in future studies. The gene discussed is RBM3; the disease is ovarian carcinoma.